when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Wegovy · news · pharmadog

← back to Wegovy

News mentioning Wegovy

101 stories

Jun 1, 26STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and morestat

Jun 1, 26CDC says containing the spread of Ebola is top prioritystat

Jun 1, 26STAT+: Medicare still won’t say how much covering obesity drugs will coststat

May 29, 26Which vaccines will curb the Ebola outbreak? WHO debatesstat

May 29, 26Opinion: I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’stat

May 28, 26CVS obesity drug deal puts Lilly on equal footing with Novobiopharma dive

May 19, 26STAT+: Virginia governor vetoes legislation to create an advisory panel to lower the cost of prescription drugsstat

May 19, 26STAT+: This spine surgery usually costs $1,400. Under No Surprises Act arbitration? $34,000stat

May 19, 26STAT+: Canadian medical societies lack sufficient conflict-of-interest policies, study findsstat

May 19, 26STAT+: A new ranking of pharma companies by R&D performancestat

May 19, 26STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much morestat

May 19, 26STAT+: Eli Lilly tops prominent rankings on pharma R&D performancestat

May 18, 26STAT+: Maryland state affordability board places a price cap on Ozempicstat

May 13, 26Lilly data point to ‘maintenance’ strategies for GLP-1 weight lossbiopharma dive

May 13, 26STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and morestat

May 12, 26STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and morestat

May 12, 26A year after Vertex’s big launch, pain drug research faces a pivotal momentbiopharma dive

May 11, 26Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shapeendpoints

May 7, 26Amazon adds Ozempic pill to same-day prescription drug kiosksendpoints

May 7, 26Entrada stock falls on Duchenne data; Wegovy expands accessendpoints

May 7, 26STAT+: FDA revisits a rare cancer treatment it rejected a few months agostat

May 7, 26STAT+: FDA to reconsider treatment for rare cancer after its surprise rejectionstat

May 7, 26STAT+: Next-gen Duchenne drug from Entrada disappointsstat

May 7, 26STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1Bstat

May 6, 26STAT+: Oregon hospitals won’t outsource to national physician chain after allstat

May 6, 26STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’stat

May 6, 26Novo hikes guidance on Wegovy pill’s fast sales startbiopharma dive

May 6, 26STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human diseasestat

May 6, 26STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share pricestat

May 6, 26Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressureendpoints

← prevpage 3 of 4next →